PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 18 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

22 February 2026

  1. (diff | hist) m 03:48 Prior authorisation 4,216 ±0 TierTwoTansy (talk | contribs) clarify that the figures are for one country only [rollback]
  2. (diff | hist) m 03:43 Temperature excursion 24,639 +622 ResinRhoswen (talk | contribs) de-orphan [rollback]
  3. (diff | hist) 00:59 Chain of custody 5,157 ±0 FlowTrialFraser (talk | contribs) add the difference between a batch certificate and a lot-specific one [rollback]

21 February 2026

  1. (diff | hist) 23:42 WuXi TIDES 16,434 ±0 CounterfeitCato (talk | contribs) correct the trading name — the short code and the legal name are different things [rollback]
  2. (diff | hist) m b 17:42 Satiety signalling 5,593 ±0 CategoryBot (talk | contribs) bot: flag bare reference [rollback]
  3. (diff | hist) m 17:03 Peptide content 8,404 ±0 PeakShapePol (talk | contribs) correct the water-content figure — the source reports it on a dry basis [rollback]
  4. (diff | hist) 13:20 Talk:Resin cleavage 611 +70 CouplingCillian (talk | contribs) /* Cleavage is a chemical step */ reply
  5. (diff | hist) 13:15 Talk:Test report forgery 611 +139 ForgeryFinder (talk | contribs) /* Sourcing of the forgery-pattern material */ reply
  6. (diff | hist) m b 12:40 Peptide aggregation 5,516 ±0 CategoryBot (talk | contribs) bot: sort category members [rollback]
  7. (diff | hist) 11:44 PolyPeptide Group (Hangzhou) 17,422 +860 StopperingSteff (talk | contribs) add the reception tally with its period and count stated [rollback]
  8. (diff | hist) 09:45 Talk:Resin cleavage 400 +163 ResinRhoswen (talk | contribs) /* Cleavage is a chemical step */ new section
  9. (diff | hist) 09:40 Talk:Test report forgery 400 +231 PrimarySrcPatia (talk | contribs) /* Sourcing of the forgery-pattern material */ new section
  10. (diff | hist) 06:52 Enteroendocrine L cell 5,083 ±0 GIP_Genoveva (talk | contribs) the half-life given was for the intact peptide; label it [rollback]
  11. (diff | hist) 04:55 Lyophilisation 28,679 ±0 StateBoardStace (talk | contribs) expand §Physical basis [rollback]
  12. (diff | hist) m 04:06 Contract development and manufacturing organisation 5,011 ±0 SemaglutideSasha (talk | contribs) sentence case in headings per PP:MOS [rollback]

20 February 2026

  1. (diff | hist) 19:57 USP General Chapter 71 4,657 ±0 SigFigSindri (talk | contribs) correct the resolution formula — the denominator is the sum of the widths [rollback]
  2. (diff | hist) 16:55 Regulatory status by jurisdiction 4,444 ±0 ColdChainCleo (talk | contribs) attribute the enforcement statement to the published policy [rollback]
  3. (diff | hist) m 13:27 Adverse effects of GLP-1 receptor agonists 5,791 ±0 GHK_Gwendolen (talk | contribs) consistent en dashes in ranges [rollback]
  4. (diff | hist) 13:20 Talk:Contraindications of incretin therapy 611 +113 ScopeSeverin (talk | contribs) /* Contraindication is a labelling concept */ reply
  5. (diff | hist) 11:55 Talk:Insulin secretion 611 +79 Peptide_Pete (talk | contribs) /* Trigger versus amplification framing */ reply
  6. (diff | hist) 10:45 Talk:Glucose-dependent insulinotropic polypeptide 1,096 +229 Ref_Desk_Ron (talk | contribs) /* Requested move: → GIP */ reply
  7. (diff | hist) 09:45 Talk:Contraindications of incretin therapy 400 +137 LabelLibby (talk | contribs) /* Contraindication is a labelling concept */ new section
  8. (diff | hist) 09:18 Talk:Insulin secretion 400 +229 BetaCellBoyd (talk | contribs) /* Trigger versus amplification framing */ new section
  9. (diff | hist) 09:08 Talk:Tirzepatide 822 +92 TirzTaxonomist (talk | contribs) /* SURPASS-2 comparator dose */ reply
  10. (diff | hist) 01:42 Multi-dose vial 24,169 ±0 FreightFenna (talk | contribs) expand §Repeated entry: coring and closure integrity [rollback]
  11. (diff | hist) m 01:02 Zhuhai Kerui Biotechnology 14,491 ±0 FirstEditFabian (talk | contribs) expand §External links [rollback]
  12. (diff | hist) m 00:06 Shenzhen Hybio Pharmaceutical 16,126 +798 DrTitration (talk | contribs) expand §Distribution and dispatch [rollback]

19 February 2026

  1. (diff | hist) 18:04 Dulaglutide 5,490 ±0 ComparisonCato (talk | contribs) attribute the potency comparison to the head-to-head trial rather than to two separate ones [rollback]
  2. (diff | hist) m 17:19 Missed dose 5,277 ±0 TrialsTabitha (talk | contribs) rm a duplicated category [rollback]
  3. (diff | hist) m 16:07 Karl Fischer titration 9,318 ±0 Areapercent_Ayo (talk | contribs) add the equilibration time to the gradient description [rollback]
  4. (diff | hist) 13:53 Insulin syringe unit conversion 6,290 ±0 DisclosureDido (talk | contribs) give the figures to a consistent number of significant figures [rollback]
  5. (diff | hist) 13:42 Talk:Tirzepatide 611 +141 TrialsTabitha (talk | contribs) /* SURPASS-2 comparator dose */ reply
  6. (diff | hist) 13:20 Talk:Bacteriostatic water 611 +105 EndotoxinEd (talk | contribs) /* The three misunderstandings */ reply
  7. (diff | hist) 13:20 Talk:ISO 9001 611 +85 VerifyVesna (talk | contribs) /* Scope is on the certificate */ reply
  8. (diff | hist) 12:30 GL Biochem (Shanghai) 16,491 ±0 SafetySignalSid (talk | contribs) add the catalogue size and label it self-reported [rollback]
  9. (diff | hist) m 11:17 Reverse-phase HPLC 5,499 ±0 Chromatokid (talk | contribs) serial comma per PP:MOS [rollback]
  10. (diff | hist) 10:15 Talk:Tirzepatide 400 +234 TirzTaxonomist (talk | contribs) /* SURPASS-2 comparator dose */ new section
  11. (diff | hist) 09:45 Talk:Bacteriostatic water 400 +119 BacWaterBarnaby (talk | contribs) /* The three misunderstandings */ new section
  12. (diff | hist) 09:45 Talk:ISO 9001 400 +151 GMP_Gita (talk | contribs) /* Scope is on the certificate */ new section
  13. (diff | hist) 04:38 Syringe dead space 20,285 +904 CostPerMgCory (talk | contribs) copyedit [rollback]
  14. (diff | hist) m 04:24 Weight regain after discontinuation 4,670 ±0 FigureFerdinand (talk | contribs) rm the reassurance sentence; the article should report, not reassure [rollback]

18 February 2026

  1. (diff | hist) m b 23:10 FLOW trial 4,583 ±0 StubSorterBot (talk | contribs) bot: flag bare reference [rollback]
  2. (diff | hist) 22:58 Global access disparity 4,391 ±0 Hedgerow_Hal (talk | contribs) ce [rollback]
  3. (diff | hist) m 22:12 Cost per milligram 4,125 ±0 AnalyticalAnnie (talk | contribs) rm the projection; nothing cited supports it [rollback]
  4. (diff | hist) 16:33 Cold chain 27,220 ±0 CagriCass (talk | contribs) expand §Failure modes [rollback]
  5. (diff | hist) m 15:44 Crude peptide 4,775 ±0 CounterfeitCato (talk | contribs) add the cross-link to the temperature-excursion article [rollback]
  6. (diff | hist) 13:15 Talk:Body composition assessment 611 +136 LeanMassLars (talk | contribs) /* Bioimpedance and hydration */ reply
  7. (diff | hist) 13:00 Talk:Residual solvent 611 +161 COA_Colwyn (talk | contribs) /* Targeted determination */ reply
  8. (diff | hist) 11:50 Talk:Syringe dead space 1,170 +104 SigFigSindri (talk | contribs) /* Needle lumen table — computed or measured? */ reply
  9. (diff | hist) 11:15 Talk:Glucose-dependent insulinotropic polypeptide 885 +412 NPOV_Nadia (talk | contribs) /* Requested move: → GIP */ reply
  10. (diff | hist) 09:52 Resin cleavage 4,310 ±0 ForestPlotFinn (talk | contribs) add the cross-link to the temperature-excursion article [rollback]
  11. (diff | hist) 09:40 Talk:Body composition assessment 400 +136 DEXA_Dilys (talk | contribs) /* Bioimpedance and hydration */ new section
  12. (diff | hist) 09:30 Talk:Glucose-dependent insulinotropic polypeptide 674 +189 MoveRequestMio (talk | contribs) /* Requested move: → GIP */ new section
  13. (diff | hist) 09:27 Talk:Syringe dead space 959 +254 SyringeSybille (talk | contribs) /* Needle lumen table — computed or measured? */ reply
  14. (diff | hist) 09:25 Talk:Residual solvent 400 +133 TechnicianTeal (talk | contribs) /* Targeted determination */ new section
  15. (diff | hist) m b 07:09 SURPASS trial programme 5,078 ±0 CategoryBot (talk | contribs) bot: expand PMID to full citation [rollback]
  16. (diff | hist) m b 06:28 Tirzepatide 8,037 ±0 ArchiveBot (talk | contribs) bot: normalise citation format [rollback]
  17. (diff | hist) 05:59 GenScript Peptides 15,685 +433 BlankVialBo (talk | contribs) expand §Distribution and dispatch [rollback]

17 February 2026

  1. (diff | hist) 22:54 GLP-1 receptor 7,570 ±0 UnitsUrsula (talk | contribs) the article treated a rodent finding as human physiology; corrected [rollback]
  2. (diff | hist) 19:58 High-performance liquid chromatography 7,231 ±0 Chromatokid (talk | contribs) expand §How the separation works [rollback]
  3. (diff | hist) 17:42 USP General Chapter 85 5,180 ±0 Retention_Time_Rae (talk | contribs) state that ultraviolet response is not uniform across impurities [rollback]
  4. (diff | hist) 17:00 Analytical method validation 5,342 ±0 Retention_Time_Rae (talk | contribs) split §Principle from §Practical limitations [rollback]
  5. (diff | hist) 15:30 Talk:Survodutide 885 +108 IncretinIvo (talk | contribs) /* Oxyntomodulin as template */ reply
  6. (diff | hist) 14:12 Talk:Syringe dead space 748 +274 UnitAuditUwe (talk | contribs) /* Needle lumen table — computed or measured? */ reply
  7. (diff | hist) 13:20 Talk:SURMOUNT trial programme 611 +100 EndpointEnid (talk | contribs) /* Curve had not plateaued */ reply
  8. (diff | hist) 11:15 Talk:Survodutide 674 +162 ProglucagonPia (talk | contribs) /* Oxyntomodulin as template */ new section
  9. (diff | hist) 10:48 Talk:Syringe dead space 537 +320 SigFigSindri (talk | contribs) /* Needle lumen table — computed or measured? */ new section
  10. (diff | hist) 09:45 Talk:SURMOUNT trial programme 400 +169 SurmountSurma (talk | contribs) /* Curve had not plateaued */ new section
  11. (diff | hist) m 00:58 AmbioPharm 14,619 ±0 SerialCommaSeb (talk | contribs) add the research-use-only statement to the lead rather than only the footer [rollback]
  12. (diff | hist) m 00:28 Receptor bias 4,477 ±0 CuriousCallum (talk | contribs) expand §The concept [rollback]

16 February 2026

  1. (diff | hist) 22:19 MOTS-c 4,670 ±0 AnalyticalAnnie (talk | contribs) add category for the peptide class [rollback]
  2. (diff | hist) m 18:03 Shanghai Wibson Biotechnology 15,440 ±0 EndotoxinEd (talk | contribs) state what the certificate supplied with orders carries [rollback]
  3. (diff | hist) m b 16:21 Vial filling and stoppering 4,833 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  4. (diff | hist) 13:20 Talk:Prior authorisation 611 +105 HarmReductionHen (talk | contribs) /* Migration to unregulated supply */ reply
  5. (diff | hist) 13:15 Talk:Analytical method validation 611 +138 AnalyticalAnnie (talk | contribs) /* Stability-indicating claims */ reply
  6. (diff | hist) m 13:09 Retatrutide 7,421 ±0 MOTSc_Mira (talk | contribs) add the discontinued indication with its date [rollback]
  7. (diff | hist) 10:44 Talk:Reconstitution calculator 1,444 +125 Ref_Desk_Ron (talk | contribs) /* Requested move: → Peptide reconstitution calculator */ reply
  8. (diff | hist) 09:45 Talk:Prior authorisation 400 +159 PriorAuthPaz (talk | contribs) /* Migration to unregulated supply */ new section
  9. (diff | hist) 09:40 Talk:Analytical method validation 400 +201 StabilityStig (talk | contribs) /* Stability-indicating claims */ new section

15 February 2026

  1. (diff | hist) m 22:37 Amino acid analysis 4,943 ±0 ColdChainCleo (talk | contribs) add the note on co-elution and what it hides [rollback]
  2. (diff | hist) 15:57 Trifluoroacetate counterion 5,116 ±0 Retention_Time_Rae (talk | contribs) correct the water-content figure — the source reports it on a dry basis [rollback]
  3. (diff | hist) 15:49 Peptide harm reduction 4,800 ±0 CostPerMgCory (talk | contribs) add the note that list price is rarely what is paid [rollback]
  4. (diff | hist) 11:45 Talk:Incretin effect 1,096 +72 NPOV_Nadia (talk | contribs) /* Type 1 diabetes section may be original research */ reply
  5. (diff | hist) 11:30 Talk:Albumin binding half-life extension 748 +191 FmocFrancis (talk | contribs) /* Manufacturing paragraph */ reply
  6. (diff | hist) 11:02 HOMA-IR 4,511 ±0 TSH_Tallulah (talk | contribs) state whether the figure is a mean or a median [rollback]
  7. (diff | hist) 09:30 Talk:Incretin effect 885 +260 Hedgerow_Hal (talk | contribs) /* Type 1 diabetes section may be original research */ reply
  8. (diff | hist) 09:05 Talk:Albumin binding half-life extension 537 +188 SPPS_Sorrel (talk | contribs) /* Manufacturing paragraph */ new section
  9. (diff | hist) 08:26 Talk:PolyPeptide Group (Hangzhou) 1,170 +144 NPOV_Nadia (talk | contribs) /* A printed trace and a filled vial are not the same object */ reply

14 February 2026

  1. (diff | hist) m 21:10 Customs seizure 4,785 ±0 GMP_Gita (talk | contribs) split the compounding position from the manufacturing position [rollback]
  2. (diff | hist) 20:24 LEADER trial 4,799 ±0 LeanMassLars (talk | contribs) cite the trial publication rather than the sponsor press release [rollback]
  3. (diff | hist) 19:14 Injection site rotation 4,872 ±0 SharpsSukhi (talk | contribs) the rounding in the table lost a decimal place that matters at low doses [rollback]
  4. (diff | hist) 16:55 VendorInvestigate 5,067 ±0 CostPerMgCory (talk | contribs) expand §Use on this wiki [rollback]
  5. (diff | hist) 15:27 Flourishglobal Peptide Biotech 14,771 +220 ShortageShona (talk | contribs) state which lines are held in regional stock [rollback]
  6. (diff | hist) 15:22 Talk:Incretin effect 674 +330 NPOV_Nadia (talk | contribs) /* Type 1 diabetes section may be original research */ new section
  7. (diff | hist) 15:09 Solid-phase peptide synthesis 5,359 ±0 HarmReductionHen (talk | contribs) expand §Scale and its limits [rollback]
  8. (diff | hist) m b 14:34 PeptideMeter 4,925 ±0 ArchiveBot (talk | contribs) bot: normalise citation format [rollback]
  9. (diff | hist) 13:05 Talk:Customs seizure 611 +144 ImportPolicyIggy (talk | contribs) /* Jurisdiction confound */ reply
  10. (diff | hist) 11:40 Talk:AmbioPharm 1,170 +215 Retention_Time_Rae (talk | contribs) /* Should the stock position sit in §Operations or §Reception? */ reply
  11. (diff | hist) 10:58 Talk:SinoPep 1,170 +154 COA_Colwyn (talk | contribs) /* Whether the counter-ion figure belongs in the lead */ reply
  12. (diff | hist) 09:40 Hypoglycaemia 4,473 ±0 NAION_Noel (talk | contribs) add category for adverse effects [rollback]